Related Experiment Videos
Chronic myelogenous leukemia: molecular and cellular aspects
G Pasternak1, A Hochhaus, B Schultheis
1III. Medizinische Klinik, Klinikum Mannheim der Universität Heidelberg, Mannheim, Germany.
Journal of Cancer Research and Clinical Oncology
|January 8, 1999
Summary
Chronic myelogenous leukemia (CML) involves the Philadelphia chromosome and BCR/ABL fusion gene, leading to uncontrolled cell growth. New therapies target BCR/ABL, offering improved treatment options for this leukemia.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Chronic myelogenous leukemia (CML) originates in bone marrow stem cells, characterized by excessive granulocyte proliferation.
- The disease progresses to acute leukemia within 4-6 years.
- CML is linked to the Philadelphia chromosome (t(9;22) translocation) and the BCR/ABL fusion gene.
Purpose of the Study:
- Investigate the role of the BCR/ABL fusion protein in CML pathogenesis.
- Explore the impact of BCR/ABL on cell adhesion and its implications for leukemic cell circulation.
- Identify novel therapeutic strategies for CML based on molecular and cellular understanding.
Main Methods:
- Analysis of the BCR/ABL fusion gene and its protein product.
- Studies on cellular adhesion, including integrin expression in CML cells.
- Development and evaluation of new therapeutic approaches, such as tyrosine kinase inhibitors and immunotherapy.
Main Results:
- The BCR/ABL fusion gene produces a hyperactive tyrosine kinase, driving cellular transformation.
- BCR/ABL can enhance fibronectin adhesion via integrin upregulation under specific conditions.
- CML progenitors exhibit altered adhesion properties, contributing to disease progression.
Conclusions:
- The BCR/ABL oncoprotein is central to CML development and progression.
- Targeting BCR/ABL and related pathways offers promising therapeutic avenues.
- Allogeneic stem cell transplantation remains the only curative option, but novel treatments are emerging.